Literature DB >> 27730303

15-0600-Dr. Fox's response to letter to the editor.

Elizabeth Fox1, Frank M Balis2.   

Abstract

Entities:  

Year:  2016        PMID: 27730303      PMCID: PMC5180204          DOI: 10.1007/s00280-016-3162-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  3 in total

1.  Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors.

Authors:  Elizabeth Fox; Brigitte C Widemann; Devang Pastakia; Clara C Chen; Sherry X Yang; Diane Cole; Frank M Balis
Journal:  Cancer Chemother Pharmacol       Date:  2015-10-20       Impact factor: 3.333

2.  In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).

Authors:  Philippe Labrie; Shawn P Maddaford; Jacques Lacroix; Concettina Catalano; David K H Lee; Suman Rakhit; René C Gaudreault
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

3.  Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects.

Authors:  M Bauer; M Zeitlinger; D Todorut; M Böhmdorfer; M Müller; O Langer; W Jäger
Journal:  Pharmacology       Date:  2012-11-07       Impact factor: 2.547

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.